

Collaboration in Alzheimer's disease & beyond: the present and the future of IMI initiatives in neurodegeneration

Agenda

15.03.2017 • Meeting facilities, 1st floor, IMI Programme Office
Avenue de la Toison d'or 56-60 • 1060 Brussels • Belgium

Wednesday 15 March

- 09:30 *Welcome coffee & registration*
- 10:00 – 10:05 **Welcome**
Pierre Meulien, IMI Executive Director
- 10:05 – 11:30 **Presentations of IMI neurodegeneration projects: part I**
- AETIONOMY: Organising mechanistic knowledge about neurodegenerative diseases for the improvement of drug development and therapy**
Martin Hofmann-Apitius, Fraunhofer Institute for Algorithms and Scientific Computing (SCAI)
- EMIF-AD: European Medical Information Framework (Alzheimer's disease)**
Simon Lovestone, University of Oxford & Pieter Jelle Visser, VU University Medical Center Amsterdam
- EPAD: European prevention of Alzheimer's dementia consortium**
Serge Van der Geyten, Janssen & Craig Ritchie, University of Edinburgh
- AMYPAD: Amyloid imaging to prevent Alzheimer's disease**
Gill Farrar, GE Healthcare & Frederik Barkhof, VU University Medical Center Amsterdam
- ROADMAP: Real world outcomes across the AD spectrum for better care: multi-modal data access platform**
Catherine Reed, Eli Lilly
- MOPEAD: Models of patient engagement for Alzheimer's disease**
Mercè Boada, Fundació ACE & Laura Campo, Eli Lilly
- 11:30 – 11:45 *Coffee break*

- 11:45 – 13:00 **Presentations of IMI neurodegeneration projects: part II**
- PRISM: Psychiatric Ratings using Intermediate Stratified Markers: providing quantitative biological measures to facilitate the discovery and development of new treatments for social and cognitive deficits in AD, SZ, and MD**
Bernd Sommer, Boehringer Ingelheim
- ADAPTED: Alzheimer's disease apolipoprotein pathology for treatment elucidation and development**
Agustín Ruiz, Fundació ACE & Margot Bakker, AbbVie
- PHAGO: Inflammation and AD: modulating microglia function - focussing on TREM2 and CD33**
Harold Neumann, University Hospital Bonn & Andreas Ebnet, Janssen
- IMPRIND: Inhibiting Misfolded protein propagation in neurodegenerative diseases**
George Tofaris, University of Oxford & Kenneth Tistrup, Lundbeck
- Data quality in preclinical research and development (upcoming project)**
Thomas Steckler, Janssen
- 13:00 – 14:00 *Networking lunch*
- 14:00 – 14:45 **Lecture on Alzheimer's disease**
Craig Ritchie, Professor of the Psychiatry of Ageing, University of Edinburgh
Jean Georges, Executive Director, Alzheimer Europe
- 15:00 – 15:30 **Introduction to the IMI public-private partnership including IP rules**
Elisabetta Vaudano, Principal Scientific Manager, IMI
Magali Poinot, Advisor to the Executive Director, IMI
- 15:30 – 16:00 **Presentation of the priorities for 2017 onwards, strategy and future directions by the IMI Strategic Governing Group (SGG) Neurodegeneration**
Luc Truyen, Co-Chair SGG Neurodegeneration, Janssen
- 16:00 – 18:00 **Input, feedback and discussion with stakeholders and partners**
Chaired by Elisabetta Vaudano, IMI
- 18:00 *End of meeting*
- 18:30 – 21:00 *Networking cocktail & dinner at The Hotel, Boulevard de Waterloo 38, Brussels*
- 21:00 *End of event*